雌激素与乳腺癌
雌激素一直被认为与乳腺癌风险增加相关,但新证据提示孕激素(内源性孕酮或合成孕激素)才是看似雌激素相关乳腺癌风险的主要激素驱动因素。雌激素可能通过诱导孕酮受体间接放大孕酮信号。大型激素避孕研究提示风险小幅增加主要归因于孕激素而非雌激素;雌激素联合孕激素的激素替代治疗(HRT)在绝经后女性中一致显示乳腺癌风险增加,而单用雌激素HRT对自然或手术绝经女性乳腺癌风险影响很小。
要点
- 孕激素可能是看似雌激素相关乳腺癌风险的主要驱动因素,雌激素通过诱导孕酮受体间接放大孕酮信号。
- 大型激素避孕研究提示乳腺癌风险小幅增加主要归因于孕激素而非雌激素。
- 雌激素联合孕激素HRT在绝经后女性中一致显示乳腺癌风险增加,单用雌激素HRT对自然或手术绝经女性影响很小。
核心结论
- 综合证据提示雌激素HRT可能对围绝经期或绝经后女性(包括乳腺癌幸存者)以及因预防卵巢癌行预防性卵巢切除术的年轻BRCA1/2携带者带来健康获益。
主要发现
- 大型激素避孕研究提示激素避孕药相关的乳腺癌风险小幅增加主要归因于孕激素而非雌激素。
- 雌激素联合孕激素HRT在绝经后女性中一致显示乳腺癌风险增加,而单用雌激素HRT对自然或手术绝经女性乳腺癌风险影响很小。
- 女性健康倡议(WHI)随机试验的长期随访提示单用雌激素可能获益。
- 近期数据提示辅助生殖技术(ART)期间内源性雌激素升高对乳腺癌风险或复发几乎没有不良影响,甚至可能降低风险。
- 越来越多的证据提示抑制孕酮信号是抗雌激素药物降低风险和治疗效果的关键机制。
临床怎么用
- 雌激素HRT已显示一系列确证获益,包括改善绝经症状和改善骨骼健康。
- 综合证据提示雌激素HRT可能对围绝经期或绝经后女性(包括乳腺癌幸存者)以及因预防卵巢癌行预防性卵巢切除术的年轻BRCA1/2携带者带来健康获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Estrogens have been associated with an increase in breast cancer risk. Yet emerging clinical and experimental evidence points to progestogens [endogenous progesterone or synthetic progesterone (progestin)] as the primary hormonal driver underlying seemingly estrogen-associated breast cancer risk. Estrogens may contribute to breast cancer risk indirectly by induction of the progesterone receptor and thus amplifying progesterone signaling. Large studies of hormonal contraceptives suggest that the small increase in breast cancer risk from hormonal contraceptives is mainly attributable to progestins, not estrogens. Estrogen-plus-progestin hormone replacement therapy (HRT) has consistently shown an increase in breast cancer risk among postmenopausal women, whereas estrogen-alone HRT has little impact on breast cancer risk in naturally or surgically menopausal women. In particular, the long-term follow-up of the Women's Health Initiative (WHI) randomized trials suggests a benefit of estrogen alone. Recent data further indicate that endogenously elevated estrogen during assisted reproductive technology (ART) exhibits little adverse effect on or potentially a reduction in breast cancer risk and recurrence. Also, accumulating evidence suggests that inhibition of progesterone signaling is a critical mechanism underlying the risk-reducing and therapeutic effects of antiestrogens. Estrogen HRT has shown an array of proven benefits, including ameliorating menopausal symptoms and improving bone health. Collective evidence thus suggests that estrogen HRT is likely to offer health benefits to perimenopausal or postmenopausal women, including breast cancer survivors, as well as young BRCA1/2 carriers with prophylactic oophorectomy for ovarian cancer prevention.
引用
- Kim J, Munster PN. Estrogens and breast cancer. Ann Oncol. 2024. PMID: 39522613. doi:10.1016/j.annonc.2024.10.824
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。